Her2 positive and triple negative breast cancer patients with clinically negative nodes at diagnosis and breast pathologic complete response may spare axillary surgery after neoadjuvant treatment

Siso C.; Esgueva A.; Rodriguez R.; Espinosa M.; Cordoba O.; Rubio I.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Her2 positive and triple negative breast cancer patients with clinically negative nodes at diagnosis and breast pathologic complete response may spare axillary surgery after neoadjuvant treatment

【24h】

Her2 positive and triple negative breast cancer patients with clinically negative nodes at diagnosis and breast pathologic complete response may spare axillary surgery after neoadjuvant treatment

机译：HER2阳性和三重阴性乳腺癌患者诊断和乳房病理完全应答的临床阴性节点可能在Neoadjuvant治疗后腋窝手术备用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共1页
作者
Siso C.; Esgueva A.; Rodriguez R.; Espinosa M.; Cordoba O.; Rubio I.;
展开▼
作者单位

Hosp Univ Vall dHebron Breast Canc Unit Barcelona Spain;

Hosp Univ Vall dHebron Breast Canc Unit Barcelona Spain;

Hosp Univ Vall dHebron Breast Canc Unit Barcelona Spain;

Hosp Univ Vall dHebron Breast Canc Unit Barcelona Spain;

Hosp Univ Vall dHebron Breast Canc Unit Barcelona Spain;

Hosp Univ Vall dHebron Breast Canc Unit Barcelona Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Her2 positive and triple negative breast cancer patients with clinically negative nodes at diagnosis and breast pathologic complete response may spare axillary surgery after neoadjuvant treatment [J] . Siso C., Esgueva A., Rodriguez R., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：HER2阳性和三重阴性乳腺癌患者诊断和乳房病理完全应答的临床阴性节点可能在Neoadjuvant治疗后腋窝手术备用
2. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab [J] . Shinde Arvind M., Zhai Jing, Yu Kim Wai, The Breast : . 2015,第1期

机译：无蒽环类新辅助化疗加卡铂和紫杉醇联合或不联合曲妥珠单抗后，三阴性，HER2阳性和激素受体阳性的乳腺癌的病理完全缓解率
3. Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer [J] . Mette S. van Ramshorst, Suzana C. Teixeira, Bas B. Koolen, Cancer Imaging . 2017,第Suppla1期

机译：18F-FDG PET / CT反应评估在三阴性和HER2阳性乳腺癌新辅助治疗期间腋窝淋巴结的附加价值
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. Preclinical exploration of novel small molecules as anticancer agents in triple-negative and HER2/neu-positive breast cancers. [D] . Weng, Shu-Chuan. 2008

机译：在三阴性和HER2 / neu阳性乳腺癌中作为抗癌药的新型小分子的临床前探索。
6. Pathologic complete response rates in triple-negative HER2-positive and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab [O] . Arvind M. Shinde, Jing Zhai, Kim Wai Yu, -1

机译：无蒽环类新辅助化疗加卡铂和紫杉醇联合或不联合曲妥珠单抗后三阴性HER2阳性和激素受体阳性的乳腺癌的病理完全缓解率
7. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab [O] . Arvind M. Shinde, Jing Zhai, Kim Wai Yu, 2015

机译：在蒽环霉素的Neoadjuvant化疗后三阴性，HER2阳性和激素受体阳性乳腺癌的病理完全反应率与Carboplatin和Parlitaxel有或没有曲妥珠单抗

Her2 positive and triple negative breast cancer patients with clinically negative nodes at diagnosis and breast pathologic complete response may spare axillary surgery after neoadjuvant treatment

著录项

相似文献

相关主题

期刊订阅